Phase 1 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form agreeing to take part in the study.
• People aged 18 to 75 years old.
• People who have been diagnosed with a solid tumour that has spread or come back, and where testing has confirmed the tumour is infected with a virus called HPV18.
• People whose cancer has not responded to past treatments and for whom no other effective treatment options are currently available.
• People whose tumour tests positive for HPV18 and who carry a specific genetic marker called HLA-DRB1*0901.
• People who are generally well enough to care for themselves and carry out light activities (this is measured using a standard scale called ECOG, with a score of 0 or 1).
• People with a life expectancy of at least 3 months.
• People who have at least one tumour that can be measured using standard imaging guidelines.
• People whose blood and organ function meet specific minimum levels, including white blood cells, platelets, haemoglobin, lymphocytes, liver enzymes, kidney function, blood clotting, heart function, and blood oxygen levels (confirm with trial site for exact values).
• People who are able to use effective contraception throughout the entire trial and for at least one year after receiving the study treatment. Women who could become pregnant must return a negative pregnancy test within 7 days before the blood collection procedure.

Who may not be able to join:

• People who have had a known allergic reaction to cyclophosphamide or fludarabine, or who are known to be allergic to any ingredient used in this study.
• People who have received systemic cancer treatments — including chemotherapy, large-area radiotherapy, targeted therapy, immunotherapy, or biological therapy — within 4 weeks before the blood collection procedure, or certain oral or herbal cancer medicines within 2 weeks before that procedure.
• People who have taken part in another clinical trial or received an experimental drug within 4 weeks before the blood collection procedure.
• People who have previously received any form of cell therapy treatment.
• People who have had major surgery within 4 weeks, or minor surgery within 2 weeks, before the blood collection procedure.
• People who still have significant side effects from previous cancer treatments that have not settled to a mild level before the blood collection procedure.
• People who have received a live or adenovirus-based vaccine within 4 weeks before the blood collection procedure.
• People who have cancer that has spread to the brain or central nervous system and is causing symptoms.
• People with significant heart symptoms or heart conditions that are not well controlled.
• People with serious or uncontrolled conditions affecting the body as a whole, or any unstable ongoing illness.
• People who have had an active infection requiring antibiotic or antiviral treatment within 2 weeks before the blood collection procedure.
• People who have an active autoimmune disease or a history of autoimmune disease.
• People who have taken immune-suppressing medicines, steroids, or immune-modifying drugs within 2 weeks before the blood collection procedure.
• People who have another current cancer, except in specific situations where a previous cancer was fully treated and has shown no signs of returning for at least 2 years (confirm with trial site).
• People who have had a serious blood clot (grade 3 or above) within the past 6 months, or who are currently taking blood-thinning or clot-dissolving medications due to high clot risk.
• People known to have HIV, syphilis, active hepatitis B, or active hepatitis C infection.
• People who have had an organ transplant or a transplant using another person's cells.
• People who have had active tuberculosis within the past year, or who have not completed at least one year of tuberculosis treatment before the blood collection procedure.
• People who are pregnant, breastfeeding, or whose pregnancy test returns a positive result before joining the trial.
• People who the trial doctors consider unsuitable for participation for other reasons, such as concerns about their ability to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.